Orforglipron and retatrutide sit at opposite ends of the metabolic-drug spectrum. Orforglipron is an oral non-peptide small molecule that targets GLP-1 alone, while retatrutide is an injectable peptide that targets three receptors at once. They also differ sharply in how far along each is, so the evidence behind them is not on equal footing.
Reviewed for accuracy · Last reviewed July 8, 2026The most concrete differences are practical. Orforglipron is a once-daily pill that trials reported can be taken without food or water restrictions, whereas retatrutide is a once-weekly subcutaneous injection that requires reconstitution and titration. Orforglipron also has completed Phase 3 programs and was under FDA review as of 2026, while retatrutide remains investigational with only Phase 2 data, so their evidence bases differ in both size and maturity.
Mechanistically they are not the same kind of drug. Orforglipron acts on the GLP-1 receptor alone as a small molecule, while retatrutide is a peptide that adds GIP and glucagon on top of GLP-1. Whether targeting three receptors translates into a meaningful real-world difference is not something the current evidence lets anyone state as fact, and cross-trial comparisons between a daily oral agent and a weekly injectable are not reliable.
Both reported predominantly gastrointestinal side effects (nausea, vomiting, diarrhea) that were dose-related and managed with gradual escalation. Neither of these summaries is a substitute for medical advice about which, if either, is appropriate, and independently sourced material carries none of the testing a regulated product does.
This page is an independent educational reference and is not medical advice. Talk to a doctor before starting or adjusting any compound.